Industry, Cancer Groups Draft Blueprint For PD-1 Companion Dx Approvals
Drug and test firms want to standardize FDA's companion diagnostic assessments for the high-profile new class of PD-1/PD-LI immunotherapy cancer drugs, an issue discussed at a recent FDA/cancer groups meeting.
You may also be interested in...
Immuno-oncology’s challenge is to orchestrate a biomarker program in a highly competitive drug development landscape knowing that prior to having significant clinical experience, the program is unlikely to yield the kinds of binary measurements used to define and select a patient population for a targeted therapy.
Lung cancer wasn’t viewed traditionally as a tumor that would respond to immunotherapy. But with checkpoint inhibitor data looking promising, big pharma is diving in and prioritizing the disease, reeled in by the large patient population and high unmet need.
The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.